Agency Information Collection Activities; Proposed Collection; Comment Request; FDA Food Safety and Nutrition Survey, 61457-61459 [2024-16832]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
userfees.fda.gov/OA_HTML/
omufaCAcdLogin.jsp.
A user fee identification (ID) number
will be generated. Payment must be
made in U.S. currency by electronic
check or wire transfer, payable to the
order of the Food and Drug
Administration. The preferred payment
method is online using electronic check
(Automated Clearing House (ACH) also
known as eCheck).
FDA has partnered with the U.S.
Department of the Treasury to use
Pay.gov, a web-based payment
application, for online electronic
payment. The Pay.gov feature is
available on the FDA website after
completing the OTC Monograph User
Fee Cover Sheet and generating the user
fee ID number. Secure electronic
payments can be submitted using the
User Fees Payment Portal at https://
userfees.fda.gov/pay. (Note: Only full
payments are accepted through https://
userfees.fda.gov/pay. No partial
payments can be made online). Once an
invoice is located, ‘‘Pay Now’’ should be
selected to be redirected to Pay.gov.
Electronic payment options are based on
the balance due. Payment by credit card
is available for balances that are less
than $25,000 (Discover, VISA,
MasterCard, American Express). If the
balance exceeds this amount, only the
ACH option is available. Payments must
be made using U.S. bank accounts as
well as U.S. credit cards.
For payments made by wire transfer,
include the unique user fee ID number
to ensure that the payment is applied to
the correct fee(s). Without the unique
user fee ID number, the payment may
not be applied, which could result in
FDA not filing an OMOR request, or
other consequences of nonpayment. The
originating financial institution may
charge a wire transfer fee. Applicable
wire transfer fees must be included with
payment to ensure fees are fully paid.
Questions about wire transfer fees
should be addressed to the financial
institution. The account information for
wire transfers is as follows: U.S.
Department of the Treasury, TREAS
NYC, 33 Liberty St., New York, NY
10045, Acct. No.: 75060099, Routing
No.: 021030004, SWIFT: FRNYUS33. If
needed, FDA’s tax identification
number is 53–0196965.
Dated: July 26, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–16878 Filed 7–30–24; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–3029]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; FDA Food Safety
and Nutrition Survey
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed reinstatement
of an existing collection of information,
and to allow 60 days for public
comment in response to the notice. This
notice solicits comments on a collection
of information used to conduct a
voluntary consumer survey entitled,
‘‘FDA Food Safety and Nutrition
Survey.’’
SUMMARY:
Either electronic or written
comments on the collection of
information must be submitted by
September 30, 2024.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
September 30, 2024. Comments received
by mail/hand delivery/courier (for
written/paper submissions) will be
considered timely if they are received
on or before that date.
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
61457
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2024–N–3029 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; FDA
Food Safety and Nutrition Survey.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
E:\FR\FM\31JYN1.SGM
31JYN1
61458
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
5733, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3521), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed reinstatement
of an existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Food Safety and Nutrition Survey
OMB Control Number 0910–0345—
Reinstatement
Under section 1003(b)(2) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 393(b)(2)), we are authorized
to conduct research relating to foods
and to conduct educational and public
information programs relating to the
safety of the nation’s food supply. In the
past, FDA has conducted two separate
surveys, a Food Safety Survey and a
Health and Diet Survey, to measure
consumers’ knowledge, attitudes, and
beliefs about food safety and nutrition
issues. These surveys have been
conducted every 3 to 5 years since the
1980s. In the Federal Register of August
14, 2018 (83 FR 40293), we announced
the combination of these two surveys,
which will now be the FDA Food Safety
and Nutrition Survey (FSANS). Data
from FDA’s food safety and nutrition
surveys have been used to support
rulemaking and educational campaigns
and to measure progress toward Healthy
People 2010, 2020, and 2030 food safety
goals. The proposed 2024 FSANS will
contain many of the same questions and
topics as the previous surveys to
facilitate measuring trends in food
safety and diet knowledge, attitudes,
and behaviors over time. The proposed
survey will also be updated to explore
emerging consumer food safety and
nutrition topics and to expand
understanding of previously asked
topics.
The 2024 FSANS will be both a
paper-and-pencil and web-based survey.
Respondents will be contacted by postal
mail, using an addressed-based
sampling frame. Once contacted,
respondents will be encouraged to take
the survey online. A paper-and-pencil
version of the survey will be mailed to
those who do not initially take the webbased version of the survey. One
randomly selected adult from each
sampled household will be invited to
participate in the survey using the
Hagen-Collier method.1 A total of 5,000
respondents will be surveyed. We will
sample approximately 25,000
households to offset nonresponding
households and ineligible addresses and
achieve 5,000 adult respondents.
Participation in the survey will be
voluntary. Cognitive interviews and a
pre-test will be conducted prior to
fielding the survey.
Description of Respondents:
Respondents to this collection of
information are individuals who are
adults, age 18 and older, drawn from the
50 states and the District of Columbia.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Total annual
responses
Average burden
per response
Total
hours
Cognitive interview screener ............
Cognitive interview ...........................
Pretest ..............................................
Mail survey .......................................
75
18
100
5,000
1
1
1
1
75
18
100
5,000
0.083 (5 minutes) ............................
1 .......................................................
0.33 (20 minutes) ............................
0.33 (20 minutes) ............................
6
18
33
1,650
Total ..........................................
........................
..........................
5,193
..........................................................
1,707
1 There
lotter on DSK11XQN23PROD with NOTICES1
Number of
responses per
respondent
Number of
respondents
Activity
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA’s burden estimate is based on the
Agency’s prior experience with food
safety and nutrition surveys. We will
use a cognitive interview screener with
1 In this method, we randomly select a category
based on gender and age (based on the gender-age
composition of the household), and then take the
adult in that selected category.
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
75 individuals to recruit prospective
interview participants for a total of 18
E:\FR\FM\31JYN1.SGM
31JYN1
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
individuals. We estimate that it will
take each screener respondent
approximately 5 minutes (0.083 hours)
to complete the cognitive interview
screener, for a total of 6 hours. We will
conduct cognitive interviews with 18
participants. We estimate that it will
take each participant approximately 1
hour to complete the interview, for a
total of 18 hours. Prior to the
administration of the surveys, the
Agency plans to conduct a pretest to
identify and resolve potential survey
administration problems. The pretest
will be conducted with 100 participants;
we estimate that it will take each
participant 20 minutes (0.33 hours) for
the pretest for a total of 33 hours. We
estimate that 5,000 eligible adults will
participate in the survey with each
taking 20 minutes (0.33 hours), for a
total of 1,650 hours. Thus, the total
estimated burden is 1,707 hours.
Dated: July 26, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–16832 Filed 7–30–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–3480]
Animal Drug User Fee Rates and
Payment Procedures for Fiscal Year
2025
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) is
announcing the fee rates and payment
procedures for fiscal year (FY) 2025
animal drug user fees. The Federal
Food, Drug, and Cosmetic Act (FD&C
Act), as amended by the Animal Drug
User Fee Amendments of 2023 (ADUFA
V), authorizes FDA to collect user fees
for certain animal drug applications and
supplemental animal drug applications,
for certain animal drug products, for
certain establishments where such
products are made, and for certain
sponsors of such animal drug
applications and/or investigational
animal drug submissions. This notice
establishes the fee rates for FY 2025.
DATES: The application fee rates apply
to applications submitted on or after
October 1, 2024, and will remain in
effect through September 30, 2025.
FOR FURTHER INFORMATION CONTACT: Visit
FDA’s website at: https://www.fda.gov/
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
industry/fda-user-fee-programs/animaldrug-user-fee-act-adufa or contact Lisa
Kable, Center for Veterinary Medicine
(HFV–10), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–6888,
Lisa.Kable@fda.hhs.gov. For general
questions, you may also email FDA’s
Center for Veterinary Medicine (CVM)
at: cvmadufa@fda.hhs.gov.
For questions relating to this notice:
Olufunmilayo Ariyo, Office of Financial
Management, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20903, 240–
402–4989; or the User Fee Support Staff
at OO-OFBAP-OFM-UFFS-Government@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 740(a) of the FD&C Act (21
U.S.C. 379j–12), as amended by ADUFA
V, establishes four different types of
user fees: (1) fees for certain animal drug
applications and supplemental animal
drug applications; (2) annual fees for
certain animal drug products; (3) annual
fees for certain establishments where
such products are made; and (4) annual
fees for certain sponsors of animal drug
applications and/or investigational
animal drug submissions. When certain
conditions are met, FDA will waive or
reduce fees per section 740(d) of the
FD&C Act.
For FYs 2024 through 2028, section
740(b)(1) of the FD&C Act establishes
the base revenue amount for each fiscal
year. Per section 740(c)(2) and (3) of the
FD&C Act, the base revenue amounts
established for fiscal years after FY 2024
are subject to adjustment for inflation
and workload. Beginning in FY 2025,
the annual fee revenue amount is also
subject to an operating reserve
adjustment to allow FDA to adjust the
fee revenue amount to maintain a
specified operating reserve of carryover
user fees, per section 740(c)(4) of the
FD&C Act. FDA may increase the fee
revenue amount to maintain a 12-week
minimum. If FDA has an excess
operating reserve, FDA will decrease the
fee revenue amount so that FDA has 22
weeks of operating reserve for FY 2025,
20 weeks for FY 2026, 18 weeks for FY
2027, and 16 weeks for FY 2028.
Per section 740(b)(2) of the FD&C Act,
fees for applications, establishments,
products, and sponsors are to be
established each year by FDA so that the
percentages of the total revenue that are
derived from each type of user fee will
be as follows: (1) revenue from
application fees shall be 20 percent of
total fee revenue; (2) revenue from
product fees shall be 27 percent of total
fee revenue; (3) revenue from
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
61459
establishment fees shall be 26 percent of
total fee revenue; and (4) revenue from
sponsor fees shall be 27 percent of total
fee revenue. The target revenue amounts
for each fee category for FY 2025 are as
follows: for application fees, the target
revenue amount is $5,701,000; for
product fees, the target revenue amount
is $7,697,000; for establishment fees, the
target revenue amount is $7,412,000;
and for sponsor fees, the target revenue
amount is $7,697,000.
For FY 2025, the animal drug user fee
rates are: (1) $581,735 for an animal
drug application; (2) $290,867 for a
supplemental animal drug application
for which safety or effectiveness data are
required, for an animal drug application
subject to the criteria set forth in section
512(d)(4) of the FD&C Act (21 U.S.C.
360b), and for an application for
conditional approval under section 571
of the FD&C Act (21 U.S.C. 360ccc) for
which an animal drug application
submitted under section 512(b)(1) of the
FD&C Act has been previously approved
under section 512(d)(1) of the FD&C Act
for another intended use; (3) $10,705 for
the annual product fee; $157,702 for the
annual establishment fee; and (4)
$137,446 for the annual sponsor fee.
FDA will issue invoices for FY 2025
product, establishment, and sponsor
fees by December 31, 2024, and
payment will be due by January 31,
2025. The application fee rates are
effective for applications submitted on
or after October 1, 2024, and will remain
in effect through September 30, 2025.
Applications will not be accepted for
review until FDA has received full
payment of application fees and any
other animal drug user fees owed under
the ADUFA program.
II. Fee Revenue Amount for FY 2025
A. Statutory Fee Revenue Amounts
Section 740(b)(1) of the FD&C Act
specifies that the base fee revenue
amount for FY 2025 for all animal drug
user fee categories totals $33,500,000.
B. Inflation Adjustment to Fee Revenue
Amount
Section 740(c)(2)(A)(ii) and (iii) of the
FD&C Act specifies that the annual fee
revenue amount is to be adjusted for
inflation increases for FY 2025 and
subsequent fiscal years using two
separate adjustments: one for personnel
compensation and benefits (PC&B) and
one for non-PC&B costs. Section
740(c)(2)(A)(ii) of the FD&C Act
specifies the component of the inflation
adjustment for payroll costs shall be one
plus the average annual percent change
in the cost of all PC&B paid per full-time
equivalent position (FTE) at FDA for the
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 89, Number 147 (Wednesday, July 31, 2024)]
[Notices]
[Pages 61457-61459]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16832]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-3029]
Agency Information Collection Activities; Proposed Collection;
Comment Request; FDA Food Safety and Nutrition Survey
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act
of 1995 (PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed reinstatement of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on a collection of information
used to conduct a voluntary consumer survey entitled, ``FDA Food Safety
and Nutrition Survey.''
DATES: Either electronic or written comments on the collection of
information must be submitted by September 30, 2024.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of September 30, 2024. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are received on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2024-N-3029 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; FDA Food Safety and Nutrition
Survey.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not
[[Page 61458]]
in the body of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North, 10A-
12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed reinstatement of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Food Safety and Nutrition Survey
OMB Control Number 0910-0345--Reinstatement
Under section 1003(b)(2) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 393(b)(2)), we are authorized to conduct research
relating to foods and to conduct educational and public information
programs relating to the safety of the nation's food supply. In the
past, FDA has conducted two separate surveys, a Food Safety Survey and
a Health and Diet Survey, to measure consumers' knowledge, attitudes,
and beliefs about food safety and nutrition issues. These surveys have
been conducted every 3 to 5 years since the 1980s. In the Federal
Register of August 14, 2018 (83 FR 40293), we announced the combination
of these two surveys, which will now be the FDA Food Safety and
Nutrition Survey (FSANS). Data from FDA's food safety and nutrition
surveys have been used to support rulemaking and educational campaigns
and to measure progress toward Healthy People 2010, 2020, and 2030 food
safety goals. The proposed 2024 FSANS will contain many of the same
questions and topics as the previous surveys to facilitate measuring
trends in food safety and diet knowledge, attitudes, and behaviors over
time. The proposed survey will also be updated to explore emerging
consumer food safety and nutrition topics and to expand understanding
of previously asked topics.
The 2024 FSANS will be both a paper-and-pencil and web-based
survey. Respondents will be contacted by postal mail, using an
addressed-based sampling frame. Once contacted, respondents will be
encouraged to take the survey online. A paper-and-pencil version of the
survey will be mailed to those who do not initially take the web-based
version of the survey. One randomly selected adult from each sampled
household will be invited to participate in the survey using the Hagen-
Collier method.\1\ A total of 5,000 respondents will be surveyed. We
will sample approximately 25,000 households to offset nonresponding
households and ineligible addresses and achieve 5,000 adult
respondents. Participation in the survey will be voluntary. Cognitive
interviews and a pre-test will be conducted prior to fielding the
survey.
---------------------------------------------------------------------------
\1\ In this method, we randomly select a category based on
gender and age (based on the gender-age composition of the
household), and then take the adult in that selected category.
---------------------------------------------------------------------------
Description of Respondents: Respondents to this collection of
information are individuals who are adults, age 18 and older, drawn
from the 50 states and the District of Columbia.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Cognitive interview screener. 75 1 75 0.083 (5 6
minutes).
Cognitive interview.......... 18 1 18 1............... 18
Pretest...................... 100 1 100 0.33 (20 33
minutes).
Mail survey.................. 5,000 1 5,000 0.33 (20 1,650
minutes).
----------------------------------------------------------------------------------
Total.................... .............. ............... 5,193 ................ 1,707
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA's burden estimate is based on the Agency's prior experience
with food safety and nutrition surveys. We will use a cognitive
interview screener with 75 individuals to recruit prospective interview
participants for a total of 18
[[Page 61459]]
individuals. We estimate that it will take each screener respondent
approximately 5 minutes (0.083 hours) to complete the cognitive
interview screener, for a total of 6 hours. We will conduct cognitive
interviews with 18 participants. We estimate that it will take each
participant approximately 1 hour to complete the interview, for a total
of 18 hours. Prior to the administration of the surveys, the Agency
plans to conduct a pretest to identify and resolve potential survey
administration problems. The pretest will be conducted with 100
participants; we estimate that it will take each participant 20 minutes
(0.33 hours) for the pretest for a total of 33 hours. We estimate that
5,000 eligible adults will participate in the survey with each taking
20 minutes (0.33 hours), for a total of 1,650 hours. Thus, the total
estimated burden is 1,707 hours.
Dated: July 26, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-16832 Filed 7-30-24; 8:45 am]
BILLING CODE 4164-01-P
